Department of Medicine Education Conference (DMEC)-17298-------3/18/2014, Stanton Gerber Hall
'Granulomatous Lung Diseases in HIV', Dima Youssef, M.D.
Dr. Youssef reports there is NOT any relevant financial interest/arrangement of affiliation with one or more organizations which could be perceived as a real or apparent
COI in the context of this presentation.
This Continuing Medical Education activity has not received support from any commercial source.
How well did this activity meet the stated learning objectives?ExcellentAbove AverageAverageBelow AveragePoor
Review the most common causes of granulomatous inflammation in the lungs          
Recognize the risk factors for developing pulmonary granulomas in HIV          
Differential diagnosis based on the setting          
Different treatment options          
Please rate this presentation:ExcellentAbove AverageAverageBelow AveragePoor
Balanced, Objective, and Evidence Based          
Appropriate for intended audience          
Rate your level of knowledge BEFORE this educational activity          
Rate your level of knowledge AFTER this educational activity          
How well did this activity address a need you have in your practice          
YesNo
Free of commercial bias    
Based on what you heard today:
Which physician attributes (core competencies) did the speaker incorporate into their presentation? Please choose all which apply:
Patient Care
Practice-Based Learning & Improvement
Medical Knowledge
System-Based Practice
Interpersonal & Communication Skills
Professionalism
A patient with HIV-AIDS on treatment for tubercular lymphadenitis develops a gross increase in the size of lymph nodes after receiving antiretroviral therapy for four weeks.
Laboratory tests show a doubling of his CD4 count. What is the most likely reason for this?
A). Multi-drug persistent TB-- B). Drug defaulter for anti- TB drugs-- C). Immune reconstitution inflammatory syndrome-- D). Poor compliance for antiretroviral therapy
ABCD
Correct answer is: C        
What new information/strategy do you plan to implement into your clinical practice?
What challenges or barriers might prevent you from implementing this new information/strategy?
What topics do you feel need to be addressed in future CME activities?
If you have questions, concerns, or comments about this activity, please contact: Barbara Sucher, M.B.A., Associate Dean for CME cmeadean@etsu.edu or 423.439.8081. Form Revised 4-2013